CJC-1295 Research

Ionescu M, Frohman LA

The landmark human trial of CJC-1295 in healthy adults ages 21–61. Participants received single or repeated subcutaneous injections of CJC-1295 or placebo in two randomized, placebo-controlled, double-blind trials. CJC-1295 produced sustained, dose-dependent increases in both GH and IGF-1 levels — with mean IGF-1 concentrations increasing 1.5 to 3-fold above baseline. Crucially, these elevations persisted for 6–8 days after a single injection due to CJC-1295’s albumin-binding mechanism, which extends its half-life far beyond native GHRH. The compound was safe and well tolerated at doses of 30–60 mcg/kg. This is the primary human pharmacokinetics and pharmacodynamics study that established CJC-1295’s clinical research profile.

Jetté L, Harvey L, Eugeni K, Levens N

A critical mechanistic study examining whether CJC-1295’s prolonged GHRH stimulation disrupts the natural pulsatile pattern of GH secretion — a key safety concern with continuous GH axis stimulation. The study found that CJC-1295 increased both trough and mean GH secretion and elevated IGF-1, while preserving natural GH pulsatility. The maintenance of pulsatile GH release is significant because pulsatile secretion is considered important for many of GH’s physiological effects. This paper established that CJC-1295 enhances GH output without flattening the natural secretion rhythm — a meaningful advantage over direct GH administration.

Jetté L, et al.

A preclinical study examining CJC-1295 in GHRH knockout mice — animals that cannot produce their own GHRH and therefore cannot generate growth hormone normally. Once-daily CJC-1295 completely normalized body weight, body length, and bone growth in these animals. The study also documented that CJC-1295 increased total pituitary RNA and GH mRNA, suggesting proliferation of somatotroph cells — meaning the peptide may not just stimulate GH release but may actually expand the pituitary’s GH-producing capacity. These findings support the potential therapeutic utility of CJC-1295 in GH deficiency states.

Ishida J, Saitoh M, Ebner N, et al.

A comprehensive review placing CJC-1295 in the broader context of GH secretagogue development. The paper traces the evolution from native GHRH through to long-acting analogs including CJC-1295 and tesamorelin, explaining how albumin-binding and structural modifications extended half-life and improved clinical utility. It also reviews the clinical development landscape — noting that while tesamorelin achieved FDA approval for lipodystrophy, CJC-1295 remains investigational. A useful reference for understanding where CJC-1295 sits relative to approved GHRH analogs and what the regulatory path for this class of compounds looks like.